Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

DARK SECRETS: 9 | Rare Historical Photos

FDA clears at-home nasal flu vaccine

AstraZeneca’s FluMist can now be taken at home

Salon

Businesses that try to come clean about their impact on nature can end up concealing more than they reveal

Humans have overfished the ocean, cleared forests, polluted water and created a climate crisis by burning fossil fuels. These actions are affecting biodiversity around the world, from remote islands to our own backyards.

The Conversation

Fortune LGBTQ+ Leaders

What will the LGBTQ+ Leaders of the future look like? Here are some of the names we expect to see a lot more of in the coming years.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Man, 27, dies weeks after receiving Covid vaccine he was wrongly invited to take by NHS

Jack Last died after having the AstraZeneca Covid jab following a ‘litany’ of errors by GP services and the NHS

The Independent UK

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

The Conversation

China detains five AstraZeneca staff over ‘data privacy and import breaches’

Detentions involve Chinese citizens who marketed cancer drugs for firm’s oncology division

The Guardian - UK

Britain could be a sci-tech superpower – if the Treasury stopped holding it back

The UK has the research base, the startups, the venture capitalists, but its presence in the global market is pitiful. The chancellor must step in

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Big Pharma Push Back On First Medicare Drug Price Cuts

Major pharmaceutical companies lashed out following a landmark deal unveiled Thursday to cut the costs of 10 key medicines, with some saying the price-setting process was not transparent.

International Business Times

Big Pharma fought to keep prices high

Big Pharma exploited patent laws to stifle competition amid Medicare price negotiations, according to a new report

Salon

As Radiotherapy Redefines Cancer Care, Here's the Stock to Buy Near 52-Week Highs

A new generation of radiotherapies are redefining cancer care, offering the potential for a more powerful treatment with fewer side effects. It could become a mainstream therapy for the big "traditional" cancers that make the disease the leading cause of death worldwide, which is why Morgan Stanley forecast the radiopharma…

Barchart

Reeves should nail down UK AstraZeneca deal. A collapse would be embarrassing

Chancellor hopes to cut state aid for Speke vaccine plant to £40m. But pro-growth Treasury must not let project slip overseas

The Guardian - UK

Blow to AstraZeneca vaccine project as Reeves plans funding cuts

Chancellor reportedly seeking to cut £20m from the £65m promised by Hunt to Merseyside manufacturing plant

The Guardian - UK

The Guardian view on record payouts for CEOs: the way they live now

Editorial: The latest High Pay Centre report confirms the persistent and damaging culture of entitlement at the top of business

The Guardian - UK

Typical FTSE 100 CEO pay hits record high of £4.2 million—but U.S. peers still earn 3 times as much

AstraZeneca’s Pascal Soriot and Rolls Royce’s Tufan Erginbilgic were among the highest-paid FTSE 100 CEOs, but what they make still trails behind the average pay of S&P 500 CEOs.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

FTSE 100 chief executive pay reaches highest level on record

Bosses of UK’s biggest companies are now paid 120 times more than average full-time worker in some instances

The Times of India

AstraZeneca's breast cancer drug fails in late-stage trial test

Truqap, the breast cancer drug which was on trial has failed to meet its main goal, the drug manufacturer AstraZeneca said on Tuesday. It said that its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall…

Barchart

1 Biopharma Stock Setting the New Standard in Cancer Care Drugs

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care…

The Guardian - UK

Is the British Gas boss really worth £8.2m?

The share price recovery has been partly driven by the surge in wholesale energy prices, which is beyond his control

Get all your
news in one place.

100's of premium titles.
One news app.

The Times of India

TOI Health News Morning Briefing| AstraZeneca's anti-cancer drug withdrawn in India, preventing dehydration in 50s, signs of heatstroke, role of fish oil supplements in cardiovascular health and more

DCGI orders withdrawal of AstraZeneca's cancer drug due to potential adverse effects

The Times of India

India's drug regulator orders withdrawal of AstraZeneca's cancer drug due to potential adverse effects

The Drug Controller General of India (DCGI) has asked all state drug regulators to withdraw AstraZeneca's anti-cancer drug Olaparib tablets. This drug which is mostly used for the treatment of patients with gBRCA mutation and advanced ovarian cancer and breast cancer has potential adverse effects, DCGI has said.

The Independent UK

Urgent call for breast cancer drug to stop women’s lives being cut short

Women with HER2-low incurable secondary disease in Scotland currently have access, while others across the UK do not

The Guardian - UK

Will AstraZeneca be the UK’s first £200bn company?

The former pharma laggard is in a race with Shell to be the first FTSE 100 stock to be valued at £200bn

Evening Standard

FTSE 100 Live 21 May: Inflation in focus after index closes slightly down

Higher-than expected UK inflation figures disappointed the City today, with shares falling as the 2.3% Consumer Price Index reading dashed hopes of a June interest rate cut.

The Guardian - UK

AstraZeneca aims to nearly double revenues to $80bn by 2030

UK’s biggest drugmaker says it plans to launch 20 major new medicines before the end of the decade

Evening Standard

'New era of growth': AstraZeneca sets out bold plans for $80bn revenues by 2030

The growth will be fuelled by 20 new drugs that are set to launch this decade

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

International Monetary Fund

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.